Search
Research
Ultraviolet radiation suppresses obesity and symptoms of metabolic syndrome independently of vitamin DUVR or sunlight exposure may be an effective means of suppressing the development of obesity and MetS, through mechanisms that are independent of vitamin D
Research
MEIS proteins as partners of the TLX1/HOX11 oncoproteinAberrant expression of the TLX1/HOX11 proto-oncogene is associated with a significant subset of T-cell acute lymphoblastic leukemias...
People
Professor Nick GottardoHead of Paediatric and Adolescent Oncology and Haematology, Perth Children’s Hospital; Co-head, Brain Tumour Research Program, The Kids Research Institute Australia
News & Events
Landmark research hopes to increase survival rates for aggressive childhood cancerA new combination of drugs could help to increase survival rates with fewer side effects for some children with one of the most aggressive forms of childhood brain cancer.
Research
Developing and characterising juvenile models of aggressive paediatric brain cancers for the evaluation of novel immunotherapies.While profound treatment responses have been realised using immunotherapy for some cancer types, this is yet to be seen for paediatric brain cancer patients.
Research
Tissue resident memory T cells: putting cancer cells to sleep and a target for therapyTissue resident memory T cells are cancer killing immune cells that have emerged as key players in immune-mediated control of solid cancers, as well as being markers of prognosis and predictors of response to immunotherapy.
Research
Integrated analysis of miRNA and mRNA expression in childhood MedulloblastomaMedulloblastoma (MB) is the most common malignant brain tumor in children and a leading cause of cancer-related mortality and morbidity.
Research
Integrated Analysis of miRNA and mRNA Expression in Childhood Medulloblastoma Compared with Neural Stem CellsMedulloblastoma (MB) is the most common malignant brain tumor in children and a leading cause of cancer-related mortality and morbidity.
Research
Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic ResponseThe functional effects of increased ERBB4 activation identify ERBB4 as a potential prognostic and therapeutic target
Research
Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in gliomaWe discovered a previously unknown major resistance mechanism in glioma in that most EGFR domain III-targeting antibodies do not neutralize EGFRvIII